Home
About
Science
Pipeline
Newsroom
Investors
Careers

MENU

Amin alrusayni

No items found

Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

About
Leadership
Board of Directors
Scientific Advisors
Tour Our Facility
Careers

Science

Pipeline
NK Cell Platform
T Cell Platform
Lifebank
Advanced Biomaterials
Manufacturing

Investors

Investor Relations
Partnerships
SEC Filings
Corporate Governance
Press Releases

Celularity Inc. © 2024. All rights reserved. Privacy Policy Terms & Conditions

Company

About
Leadership
Board of Directors
Scientific Advisors
Tour Our Facility
Careers

Science

Pipeline
NK Cell Platform
T Cell Platform
Lifebank
Advanced Biomaterials
Manufacturing

Investors

Investor Relations
Partnerships
SEC Filings
Corporate Governance
Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy Terms & Conditions

in

F.A.Q

Support Forum

Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: (908) 768 – 2170